Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Inotiv (NOTV – Research Report) today. The company’s shares opened today at $6.80.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Ligand Pharma, and Omnicell. According to TipRanks, Hewitt has an average return of 5.8% and a 44.90% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inotiv with a $21.50 average price target.
See the top stocks recommended by analysts >>
NOTV market cap is currently $175.2M and has a P/E ratio of -0.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Read More on NOTV:
